Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker; Subrato J. Deb; Min Li; Megan R. Lerner; Stan A. Lightfoot; Aurelien A. Quillet; R. Jane Hanas; Matthew Reinersman; Jess L. Thompson; Nicole T. Vu; Thomas C. Kupiec; Daniel J. Brackett; Marvin D. Peyton; Stephen M. Dubinett; Harold M. Burkhart; Russell G. Postier; Jay S. Hanas

doi:10.1080/07357907.2017.1373120

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. Hocker
, Subrato J. Deb
, Min Li
, Megan R. Lerner
, Stan A. Lightfoot
, Aurelien A. Quillet
, R. Jane Hanas
, Matthew Reinersman
, Jess L. Thompson
, Nicole T. Vu
, Thomas C. Kupiec
, Daniel J. Brackett
, Marvin D. Peyton
, Stephen M. Dubinett
, Harold M. Burkhart
, Russell G. Postier
, Jay S. Hanas

Surgery

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

Original language	English (US)
Pages (from-to)	573-585
Number of pages	13
Journal	Cancer Investigation
Volume	35
Issue number	9
DOIs	https://doi.org/10.1080/07357907.2017.1373120
State	Published - Oct 21 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1080/07357907.2017.1373120

Cite this

Hocker, J. R., Deb, S. J., Li, M., Lerner, M. R., Lightfoot, S. A., Quillet, A. A., Hanas, R. J., Reinersman, M., Thompson, J. L., Vu, N. T., Kupiec, T. C., Brackett, D. J., Peyton, M. D., Dubinett, S. M., Burkhart, H. M., Postier, R. G., & Hanas, J. S. (2017). Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. Cancer Investigation, 35(9), 573-585. https://doi.org/10.1080/07357907.2017.1373120

Hocker, JR, Deb, SJ, Li, M, Lerner, MR, Lightfoot, SA, Quillet, AA, Hanas, RJ, Reinersman, M, Thompson, JL, Vu, NT, Kupiec, TC, Brackett, DJ, Peyton, MD, Dubinett, SM, Burkhart, HM, Postier, RG & Hanas, JS 2017, 'Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients', Cancer Investigation, vol. 35, no. 9, pp. 573-585. https://doi.org/10.1080/07357907.2017.1373120

@article{57ec2da44c2d4707bbab82b5f75a659b,

title = "Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients",

abstract = "A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.",

author = "Hocker, \{James R.\} and Deb, \{Subrato J.\} and Min Li and Lerner, \{Megan R.\} and Lightfoot, \{Stan A.\} and Quillet, \{Aurelien A.\} and Hanas, \{R. Jane\} and Matthew Reinersman and Thompson, \{Jess L.\} and Vu, \{Nicole T.\} and Kupiec, \{Thomas C.\} and Brackett, \{Daniel J.\} and Peyton, \{Marvin D.\} and Dubinett, \{Stephen M.\} and Burkhart, \{Harold M.\} and Postier, \{Russell G.\} and Hanas, \{Jay S.\}",

note = "Publisher Copyright: {\textcopyright} 2017 Taylor \& Francis Group, LLC.",

year = "2017",

month = oct,

day = "21",

doi = "10.1080/07357907.2017.1373120",

language = "English (US)",

volume = "35",

pages = "573--585",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "9",

}

TY - JOUR

T1 - Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

AU - Hocker, James R.

AU - Deb, Subrato J.

AU - Li, Min

AU - Lerner, Megan R.

AU - Lightfoot, Stan A.

AU - Quillet, Aurelien A.

AU - Hanas, R. Jane

AU - Reinersman, Matthew

AU - Thompson, Jess L.

AU - Vu, Nicole T.

AU - Kupiec, Thomas C.

AU - Brackett, Daniel J.

AU - Peyton, Marvin D.

AU - Dubinett, Stephen M.

AU - Burkhart, Harold M.

AU - Postier, Russell G.

AU - Hanas, Jay S.

PY - 2017/10/21

Y1 - 2017/10/21

N2 - A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

AB - A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

UR - https://www.scopus.com/pages/publications/85029906670

UR - https://www.scopus.com/pages/publications/85029906670#tab=citedBy

U2 - 10.1080/07357907.2017.1373120

DO - 10.1080/07357907.2017.1373120

M3 - Article

C2 - 28949774

AN - SCOPUS:85029906670

SN - 0735-7907

VL - 35

SP - 573

EP - 585

JO - Cancer Investigation

JF - Cancer Investigation

IS - 9

ER -

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this